{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T07:06:36Z","timestamp":1775199996926,"version":"3.50.1"},"reference-count":41,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Supporting Project at King Saud University","award":["RSP\/2019\/45"],"award-info":[{"award-number":["RSP\/2019\/45"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>A simple, rapid, sensitive, and precise reversed-phase liquid chromatographic method was developed and validated for the simultaneous determination of four direct-acting antivirals, sofosbuvir (SF), ledipasvir (LD), declatasvir (DC), and simeprevir (SM), in their respective pharmaceutical formulations. Effective chromatographic separation was achieved on an Agilent Eclipse plus C8 column (250 mm \u00d7 4.6 mm, 5 \u00b5m) at 40 \u00b0C with gradient elution using a mobile phase composed of acetonitrile:phosphate buffer (pH 6.5). The quantification of SF and DC was based on peak area measurements at 260 nm, while the quantification of LD and SM was achieved at 330 nm. The linearity was acceptable from 1.0 to 20.0 \u03bcg\/mL for the studied drugs, with correlation coefficients &gt;0.999. The analytical performance of the newly proposed HPLC procedure was thoroughly validated according to ICH guidelines in terms of linearity, precision (RSD%, 0.39\u20131.57), accuracy (98.05\u2013101.90%), specificity, limit of detection (LOD) (0.022\u20130.039 \u03bcg\/mL), limit of quantification (LOQ) (0.067\u20130.118 \u03bcg\/mL), and robustness. The validated HPLC method was successfully used to analyze the abovementioned drugs in their pure and dosage forms without interference from common excipients present in commercial formulations.<\/jats:p>","DOI":"10.3390\/molecules25204611","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T07:23:22Z","timestamp":1602919402000},"page":"4611","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-5913","authenticated-orcid":false,"given":"Essam","family":"Ezzeldin","sequence":"first","affiliation":[{"name":"Pharmaceutical Chemistry Department, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia"},{"name":"Bioavailability Center, National Organization for Drug Control and Research (NODCAR), Giza P.O. Box 29, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisreen F.","family":"Abo-Talib","sequence":"additional","affiliation":[{"name":"Bioavailability Center, National Organization for Drug Control and Research (NODCAR), Giza P.O. Box 29, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa H.","family":"Tammam","sequence":"additional","affiliation":[{"name":"Bioavailability Center, National Organization for Drug Control and Research (NODCAR), Giza P.O. Box 29, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousif A.","family":"Asiri","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1338-706X","authenticated-orcid":false,"given":"Abd El-Galil E.","family":"Amr","sequence":"additional","affiliation":[{"name":"Pharmaceutical Chemistry Department, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia"},{"name":"Applied Organic Chemistry Department, National Research Center, Dokki, Cairo 12622, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8711-3873","authenticated-orcid":false,"given":"Abdulrahman A.","family":"Almehizia","sequence":"additional","affiliation":[{"name":"Pharmaceutical Chemistry Department, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus","volume":"17","author":"Lavanchy","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","first-page":"1351","article-title":"Hepatitis C: Diagnosis and treatment","volume":"81","author":"Wilkins","year":"2010","journal-title":"Am. Fam. Physician"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/liv.13186","article-title":"The prevalence of hepatitis C virus infection in Egypt 2015: Implications for future policy on prevention and treatment","volume":"37","author":"Kandeel","year":"2017","journal-title":"Liver Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/1871526514666141014145612","article-title":"Current Burden of Hepatitis C Virus Infection Among Injecting Drug Users: A Mini Systematic Review of Prevalence Studies","volume":"14","author":"Rafiq","year":"2014","journal-title":"Infect. Disord. Drug Targets Disord."},{"key":"ref_6","unstructured":"Goodman, L.S., Gilman, A.G., Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W., Palmer, T., Kunkel, E., and Rall, T.W. (1996). Goodman & Gilman\u2019s the Pharmacological Basis of Therapeutics, McGraw-Hill, Health Professions Division."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kwon, H.J., Xing, W., Chan, K., Niedziela-Majka, A., Brendza, K.M., Kirschberg, T., Kato, D., Link, J.O., Cheng, G., and Liu, X. (2015). Direct binding of ledipasvir to HCV NS5A: Mechanism of resistance to an HCV antiviral agent. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122844"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.virol.2014.12.018","article-title":"Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides","volume":"476","author":"Chukkapalli","year":"2015","journal-title":"Virology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e1007177","DOI":"10.1371\/journal.ppat.1007177","article-title":"HCV NS5A dimer interface residues regulate HCV replication by controlling its self-interaction, hyperphosphorylation, subcellular localization and interaction with cyclophilin A","volume":"14","author":"Shanmugam","year":"2018","journal-title":"PLoS Pathog."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/17474124.2016.1116937","article-title":"Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection","volume":"10","author":"Sundaram","year":"2016","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_12","first-page":"871","article-title":"TMC-435, an NS3\/4A protease inhibitor for the treatment of HCV infection","volume":"10","author":"Tsantrizos","year":"2009","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_13","first-page":"4508","article-title":"A new validated rp-hplc method for the simultaneous determination of simeprevir and sofosbuvir in pharmaceutical dosage form","volume":"6","author":"Subrahmanyam","year":"2016","journal-title":"Indo Am. J. Pharm. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/lt.24422","article-title":"Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation","volume":"22","author":"Crittenden","year":"2016","journal-title":"Liver Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.22159\/ajpcr.2016.v9s3.14616","article-title":"Method development and validation of ultraviolet-visible spectroscopic method for the estimation of hepatitis-c drugs-daclatasvir and sofosbuvir in active pharmaceutical ingredient form","volume":"9","author":"Chakravarthy","year":"2016","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"ref_16","first-page":"121","article-title":"Estimation and validation of sofosbuvir in bulk and tablet dosage form by rp-hplc","volume":"6","author":"Vejendla","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jpba.2015.12.045","article-title":"Characterization of forced degradation products and in silico toxicity prediction of Sofosbuvir: A novel HCV NS5B polymerase inhibitor","volume":"120","author":"Swain","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/chromsci\/bmw119","article-title":"Stability-Indicating Method and LC-MS-MS Characterization of Forced Degradation Products of Sofosbuvir","volume":"54","author":"Nebsen","year":"2016","journal-title":"J. Chromatogr. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/bmc.3690","article-title":"Novel and sensitive UPLC\u2013MS\/MS method for quantification of sofosbuvir in human plasma: Application to a bioequivalence study","volume":"30","author":"Rezk","year":"2016","journal-title":"Biomed. Chromatogr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.22159\/ijpps.2017v9i3.16185","article-title":"Bioanalytical method development and validation for the determination of sofosbuvir from human plasma","volume":"9","author":"Madhavi","year":"2017","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Semreen, M.H., Alniss, H.Y., Mousa, M.K., and Aboul-Enein, H.Y. (2019). Quick and Sensitive UPLC-ESI-MS\/MS Method for Simultaneous Estimation of Sofosbuvir and Its Metabolite in Human Plasma. Molecules, 24.","DOI":"10.3390\/molecules24071302"},{"key":"ref_22","first-page":"1","article-title":"Development and Validation of Simple UV Spectrophotometric Method for the Determination of Ledipasvir in Bulk Form and Stress Degradation Studies","volume":"3","author":"Ranjana","year":"2016","journal-title":"Inventi Rapid Pharm. Anal. Qual. Assur."},{"key":"ref_23","first-page":"1312","article-title":"New method development and validation for the determination of ledipasvir in bulk drug form by using reverse phase hplc technique","volume":"6","author":"Devilal","year":"2016","journal-title":"World J. Pharm. Pharm. Sci."},{"key":"ref_24","first-page":"1116","article-title":"An UPLC-MS\/MS Method for the Quantitation of Ledipasvir in Rat Plasma: Application to a Pharmacokinetic Study","volume":"35","author":"Zhang","year":"2016","journal-title":"Latin Am. J. Pharm."},{"key":"ref_25","first-page":"356","article-title":"Method development and validation of assay and dissolution methods for the estimation of daclatasvir in tablet dosage forms by reverse phase HPLC","volume":"3","author":"Chakravarthy","year":"2016","journal-title":"Eur. J. Pharm. Med. Res."},{"key":"ref_26","first-page":"280","article-title":"Quantitative Estimation of Daclatasvir In Drug Substances and Formulated Drug Product By UPLC","volume":"8","author":"Nadig","year":"2016","journal-title":"Der Pharm. Lett."},{"key":"ref_27","first-page":"107","article-title":"Development and validation of stability indicating RP-HPLC method for the estimation of Daclatasvir in bulk and formulation","volume":"8","author":"Sumathi","year":"2016","journal-title":"Der Pharm. Lett."},{"key":"ref_28","first-page":"1565","article-title":"Stability Indicating HPLC Method Development and Validation for Determination of Daclatasvir in Pure and Tablets Dosage Forms","volume":"3","author":"Saleh","year":"2016","journal-title":"Indo Am. J. Pharm. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpba.2016.05.016","article-title":"Development and validation of sensitive and rapid UPLC-MS\/MS method for quantitative determination of daclatasvir in human plasma: Application to a bioequivalence study","volume":"128","author":"Rezk","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/22297928.2017.1287004","article-title":"Stability-indicating HPLC-DAD Method for the Determination of Simeprevir","volume":"7","author":"Attia","year":"2017","journal-title":"Anal. Chem. Lett."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpba.2016.01.019","article-title":"Development of a simple HPLC-UV method for the determination of the hepatitis C virus inhibitor simeprevir in human plasma","volume":"121","author":"Nannetti","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchromb.2014.02.028","article-title":"Determination of simeprevir: A novel. hepatitis C protease inhibitor in human plasma by high-performance liquid chromatography-tandem mass spectrometry","volume":"958","author":"Vanwelkenhuysen","year":"2014","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_33","first-page":"555562","article-title":"Assay and Dissolution Methods Development and Validation for Simultaneous Determination of Sofosbuvir and Ledipasvir by RP-HPLC Method in Tablet Dosage Forms","volume":"1","author":"Hassouna","year":"2017","journal-title":"J. Forensic Sci. Crim. Inves"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jpba.2015.05.006","article-title":"Development of a sensitive UPLC-ESI-MS\/MS method for quantification of sofosbuvir and its metabolite. GS-331007, in human plasma: Application to a bioequivalence study","volume":"114","author":"Rezk","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.5740\/jaoacint.16-0021","article-title":"A Rapid and Optimized LC-MS\/MS Method for the Simultaneous Extraction and Determination of Sofosbuvir and Ledipasvir in Human Plasma","volume":"99","author":"Elkady","year":"2016","journal-title":"J. AOAC Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s10337-016-3179-9","article-title":"RP-HPLC Method for Simultaneous Determination of Sofosbuvir and Ledipasvir in Tablet Dosage Form and Its Application to In Vitro Dissolution Studies","volume":"79","author":"Zaman","year":"2016","journal-title":"Chromatographia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/10826076.2017.1298526","article-title":"Chromatographic analysis of ledipasvir and sofosbuvir: New treatment for chronic hepatitis C infection with application to human plasma","volume":"40","author":"Farid","year":"2017","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"976","DOI":"10.5740\/jaoacint.16-0330","article-title":"Spectrophotometric Methods for Simultaneous Determination of Sofosbuvir and Ledipasvir (HARVONI Tablet): Comparative Study with Two Generic Products","volume":"100","author":"Tammam","year":"2017","journal-title":"J. AOAC Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpba.2016.04.031","article-title":"A UHPLC-MS\/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir\/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma","volume":"125","author":"Ariaudo","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_40","unstructured":"ICH (2005). ICH Q2(R1) Validation of Analytical Procedures: Text and Methodology in pp. ICH Guideline, ICH Secretariat. Available online: http:\/\/www.ich.org."},{"key":"ref_41","unstructured":"USP (2015). USP 38\u2014NF 33 the United States Pharmacopeia and National Formulary 2015: Main Edition Plus Supplements 1 and 2, Deutscher Apotheker Verlag."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/20\/4611\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:18:59Z","timestamp":1760177939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/20\/4611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":41,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["molecules25204611"],"URL":"https:\/\/doi.org\/10.3390\/molecules25204611","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,10]]}}}